In a retrospective analysis, researchers compared survival outcomes and prognostic factors between patients with advanced-stage epithelial ovarian cancer who underwent hyperthermic intraperitoneal...
A real-world retrospective study found that adding GLP-1 receptor agonists to hormone therapy may reduce endometrial cancer risk in women with benign uterine or endometrial hyperplasia. This study was...
A retrospective cohort study compared the patient characteristics and postoperative outcomes of those with stage III or IV epithelial ovarian cancer who had same-day discharge following minimally invasive...
In their phase 3, open-label trial, Brown and colleagues set out to address the need for more effective first-line treatment strategies for fit patients with untreated CLL.
A recent phase 3 trial showed that combining nivolumab with AVD chemotherapy improves 2-year progression-free survival while also offering a superior safety profile compared with a brentuximab vedotin...
In their secondary analysis of the Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma randomized clinical trial, researchers evaluated the 5-year efficacy of...
A phase 3 trial subgroup analysis found that adding pembrolizumab to adjuvant chemotherapy may improve disease-free survival in patients with mismatch repair-deficient endometrial cancer, a population at...
A randomized trial found that radiation therapy alone provides better progression-free survival and fewer acute toxicities than chemoradiation for women with localized recurrent endometrial cancer.
This phase 3 study demonstrated that roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is noninferior to rHuEPO-α in improving hemoglobin levels for chemotherapy-induced anemia,...
Neoadjuvant nivolumab plus ipilimumab demonstrated improved event-free survival, higher pathologic complete response rates, and lower toxicity compared with chemotherapy in patients with resectable...
